Needham analyst Ryan MacDonald reiterated a Buy rating on Phreesia (NYSE:PHR) on Wednesday, setting a price target of $70, which is approximately 34.20% above the present share price of $52.16.
MacDonald expects Phreesia to post earnings per share (EPS) of -$0.17 for the first quarter of 2021.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Phreesia, with an average price target of $70.
The analysts price targets range from a high of $70 to a low of $70.
In its latest earnings report, released on 10/31/2020, the company reported a quarterly revenue of $38.46 million and a net profit of -$6.11 million. The company's market cap is $2.3 billion.
According to TipRanks.com, Needham analyst Ryan MacDonald is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 37.1% and a 67.01% success rate.
Phreesia, Inc. provides patient check-in solutions for medical practices. It provides solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform the company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a payments solution for secure processing of patient payments. Its platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. Phreesia was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in New York, NY.